Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs
"Our cells naturally become more mesenchymal over time, so PRP’s ability to potentially reverse this trend is of tremendous scientific interest"
-
These patents represent a significant turning point for Propanc and commercial potential of PRP for treating chronic diseases such as cancer and fibrosis
-
“Our first quarter delivered meaningful progress across clinical, financial, and strategic initiatives,” said James Nathanielsz, CEO of Propanc.
-
We are entering a transformative phase for the Company as we work on building our digital asset base and strengthening our balance sheet
-
We aim to leverage our public company platform to build a diversified digital asset portfolio while continuing to advance our innovative oncology pipeline.
-
This accelerates development of our clinical pipeline and leverages Hexstone’s previous investments in companies that have built digital asset treasuries.
-
This accelerates development of our clinical pipeline and leverages Hexstone’s previous investments in companies that have built digital asset treasuries.
-
Propanc announced its fiscal year-end following the filing of its annual 10-K report with the Securities and Exchange Commission on September 29, 2025.
-
A certificate of grant for Propanc’s “proenzyme composition” patent was received from the US Patent & Trademark Office.
-
Purchase of Ethereum will enhance a multi-faceted corporate strategy of cryptocurrency exposure, pharmaceutical drug development and asset acquisition.